Lenvatinib Suppresses Angiogenesis through the Inhibition of both the VEGFR and FGFR Signaling Pathways

• Główni autorzy: Kenji Ichikawa (Autor), Saori Watanabe Miyano (Autor), Yusuke Adachi (Autor), Masahiro Matsuki (Autor), Kiyoshi Okamoto (Autor), Junji Matsui (Autor)
• Format: Książka
• Wydane: Global Journal of Cancer Therapy - Peertechz Publications, 2016-07-02.
• Hasła przedmiotowe: Research Article
• Dostęp online: Connect to this object online.

<p>Lenvatinib mesilate (lenvatinib) is an oral multiple-receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of Vascular Endothelial Growth Factor Receptor (VEGFR) 1-3, Fibroblast Growth Factor Receptor (FGFR) 1-4, Platelet-Derived Growth Factor Receptor (PDGFR) α...